Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ:TARS
Want to see TARS full AI Analyst Report?
Vehicle Control, Lotilaner Ophthalmic Solution, 0.25%
Demodex Blepharitis
Phase IV
Completed
Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
Dec 13, 2023
―
Tp-03, Tp-03 Vehicle
Blepharitis, Meibomian Gland Dysfunction, Demodex Infestation
Phase II
Completed
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
Jun 27, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Tarsus Pharmaceuticals, Inc. (TARS) have in its pipeline
TARS is currently developing the following drugs: Vehicle Control, Lotilaner Ophthalmic Solution, 0.25%, Tp-03, Tp-03 Vehicle. These drug candidates are in various stages of clinical development as the company works toward FDA approval.